CEFZIL (cefprozil) by Engine Biosciences is clinical pharmacology the pharmacokinetic data were derived from the capsule formulation; however, bioequivalence has been demonstrated for the oral solution, capsule, tablet, and suspension formulations under fasting conditions. First approved in 1991.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
CEFZIL (cefprozil) is an oral second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis through beta-lactam mechanism of action. It is indicated for treatment of bacterial infections including upper and lower respiratory tract infections, otitis media, and skin infections. The drug demonstrates rapid oral absorption with peak plasma concentrations achieved within 1.5 hours and renal clearance accounting for approximately 60% of the administered dose.
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating declining revenue trajectory and potential team restructuring.
CLINICAL PHARMACOLOGY The pharmacokinetic data were derived from the capsule formulation; however, bioequivalence has been demonstrated for the oral solution, capsule, tablet, and suspension formulations under fasting conditions. Following oral administration of cefprozil to fasting subjects,…
Worked on CEFZIL at Engine Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions
Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.
Cefprozil for Oral Suspension 250 mg/5 mL, Fasting
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions
Working on CEFZIL represents a declining-phase opportunity with minimal new job creation (0 linked positions) and heavy focus on maintaining market share against generics. Career advancement is limited as the product transitions toward post-LOE status, making this role suitable primarily for those seeking stability in maintenance roles rather than growth opportunities.